1. ALLA AKTIER
  2. NYHETER
  3. CELLAVISION

CellaVision

Nyheter CellaVision Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Invitation to Presentation of the CellaVision Report for the Second Quarter 2026 on July 17, at 11:00 CEST

CellaVision AB (publ) will publish its report for the second quarter of 2026 on July 17, 2026, at 7:20 am CEST. The report will be available at www.cellavision.com.

In connection with the release of the report, analysts, investors, and media are hereby invited to a conference call and webcast at 11:00 am CEST, where Steve Ferguson, President & CEO, and Monica Jönsson, CFO, will present and comment on the report. The presentation will be in English.

To participate via webcast, please use the link below.
https://cellavision.events.inderes.com/q2-report-2026
 
To participate via conference call, please register at the link below. After registration, you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/cellavision/q2-report-2026/dial-in

No pre-registration is required. Please dial in 5-10 minutes before the scheduled start time to facilitate a timely start.

Contact

Lisa Bodily Nordqvist
Investor Relations and Corporate Communications Manager
Phone: + 46 76 345 31 87
E-mail: lisa.bodilynordqvist@cellavision.com
www.cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company’s 13 local market support organizations covering more than 40 countries. In 2025, sales were SEK 759 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

Attachments

Invitation to Presentation of the CellaVision Report for the Second Quarter 2026 on July 17, at 11:00 CEST

Datum 2026-07-03, kl 08:20
Källa MFN
Bifogade filer
Invitation to Presentation of the CellaVision Report for the Second Quarter 2026 on July 17, at 11:00 CEST